Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease
Key facts
- Who runs it
- Assistance Publique Hopitaux De Marseille
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 55 people, planned
- Started
- 24 Jun 2025
- Expected to end
- 24 Aug 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Quantitative neuromuscular MRI
- Skin biopsy
- Clinical scores
- Blood test
- Patient Report Outcomes Measures
- Record updated
- 28 October 2026
Who can take part
- Age
- 10 years to 30 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Healthy volunteer or patient who has given consent for participation in the study or, for minors, a healthy volunteer whose two parents have given consent for participation in the study
- Patient with genetically confirmed CMT1A or with a parent whose diagnosis is genetically confirmed
- Patient able to walk with or without assistance
Who cannot take part
- Helathy volunteer on long-term therapy
- Healthy volunteer with neurological disorders
- Healthy volunteer or patient with a contraindication to MRI,
- Healthy volunteers or patient under 30 kg
- Patient with other neuromuscular pathologies
- Patient in a period of exclusion from another research protocol at the time of signing the consent/non-opposition form
- Pregnant or breast-feeding women
- Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women)
- Subjects who cannot read and understand the French language well enough to be able to give their consent to participate in research
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a 2-year follow-up study of a cohort of 35 CMT1A patients and 20 healthy volunteers. The main objective is identifying prognostic markers for CMT1A using multi-omics analysis. The study is recruiting subjects between the ages of 10 and 30.
Read full original descriptionShow less
The most common inherited neuropathy is Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication of the gene expressing PMP22. CMT1A patients develop symptoms in early childhood with variable progression and there is no established therapy until now. Therapy must start in childhood, before peripheral nerves degenerate. However, we lack easily obtainable biomarkers in early disease stages.
In CMT-MODs, we will identify disease and prognostic biomarkers in young CMT1A patients.
The 2 groups in the trial
- Charcot-Marie-Tooth Neuropathy 1AOther group
Patient with genetically confirmed CMT1A or with a parent whose diagnosis is genetically confirmed,
Treatment: Quantitative neuromuscular MRI, Skin biopsy, Clinical scores, Blood test, and Patient Report Outcomes Measures
- Healthy volunteersOther group
Patient-matched controls
Treatment: Quantitative neuromuscular MRI, Skin biopsy, Clinical scores, and Blood test
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)
- Record updated
- 28 October 2026